Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer

被引：0

作者：

Oh, Do-Youn ^{[1
]}

Park, Joon Oh ^{[2
]}

Kindler, Hedy L. ^{[3
]}

Hammel, Pascal ^{[4
]}

Reni, Michele ^{[5
]}

Van Cutsem, Eric ^{[6
]}

Macarulla, Teresa ^{[7
]}

Hall, Michael J. ^{[8
]}

Arnold, Dirk ^{[9
]}

Reinacker-Schick, Anke ^{[10
]}

Tortora, Giampaolo ^{[11
]}

Algul, Hana ^{[12
]}

O'Reilly, Eileen M. ^{[13
]}

McGuiness, David ^{[14
]}

Liu, Yu-Zhen ^{[14
]}

Cui, Karen ^{[15
]}

Schlienger, Katia ^{[16
]}

Locker, Gershon Y. ^{[15
]}

Golan, Talia ^{[17
]}

机构：

[1] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul Natl Univ Hosp, Seoul, South Korea

[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Univ Paris VII, Hop Beaujon Clichy, Paris, France

[5] IRCCS Osped San Raffaele Sci Inst, Milan, Italy

[6] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Leuven, Belgium

[7] Vall Hebron Univ Hosp, Inst Oncol, Barcelona, Spain

[8] Fox Chase Canc Ctr, Philadelphia, PA USA

[9] Asklepios Tumorzentrum Hamburg Asklepios Klin Al, Hamburg, Germany

[10] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany

[11] Fdn Policlin Gemelli IRCCS, Med Oncol Unit, Rome, Italy

[12] Tech Univ Munich, Klin Rechts Isar, Munich, Germany

[13] Memorial Sloan Kettering Canc Ctr, New York, NY USA

[14] AstraZeneca, Cambridge, England

[15] AstraZeneca, Gaithersburg, MD USA

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] Tel Aviv Univ, Sheba Med Ctr, Inst Oncol, Tel Aviv, Israel

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.05.643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO31-6

引用

页码：S319 / S319

页数：1

共 50 条

[11] POLO: subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
Arnold, D.
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, M. J.
Park, J. O.
Hochhauser, D.
Oh, D. -Y
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E. M.
Bordia, S.
McGuinness, D.
Cui, K. Y.
Kindler, H. L.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 221 - 221
[12] POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Mercade, T. Macarulla
Hall, M. J.
Park, J. O.
Hochhauser, D.
Arnold, D.
Oh, D-Y.
Reinacher-Schick, A.
Tortora, G.
Algul, H.
O'Reilly, E. M.
Bordia, S.
McGuinness, D.
Cui, K. Y.
Locker, G.
Kindler, H.
ANNALS OF ONCOLOGY, 2021, 32 : S1086 - S1087
[13] Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost-Utility Analysis from the Canadian Public Payer's Perspective
Fashami, Fatemeh Mirzayeh
Levine, Mitchell
Xie, Feng
Blackhouse, Gordon
Tarride, Jean-Eric
CURRENT ONCOLOGY, 2023, 30 (05) : 4688 - 4699
[14] Germline BRCA-mutated metastatic breast cancer with positive hormone receptor
Michela Palleschi
Maria Laura Iaia
Chiara Casadei
Breast Cancer Research and Treatment, 2021, 186 : 265 - 266
[15] Germline BRCA-mutated metastatic breast cancer with positive hormone receptor
Palleschi, Michela
Iaia, Maria Laura
Casadei, Chiara
BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (01) : 265 - 266
[16] Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer
Le, Dan
Gelmon, Karen A.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (09) : 833 - 839
[17] Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer
McCrea, Charles
Hettle, Robert
Gulati, Poonam
Taneja, Ankush
Rajora, Preety
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (13) : 1021 - 1030
[18] Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
Munroe, Marklie
Kolesar, Jill
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (14) : 1037 - 1041
[19] POLO: patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
Arnold, D.
Yoo, Kyoo H.
Kindler, H. L.
McGuinness, D.
Cui, K. Y.
Joo, S.
Golan, T.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 224 - 224
[20] POLO: Patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
Kindler, H.
Yoo, H.
McGuinness, D.
Cui, K.
Joo, S.
Locker, G.
Golan, T.
ANNALS OF ONCOLOGY, 2021, 32 : S134 - S134

← 1 2 3 4 5 →